RICHMOND, Calif.,
May 10, 2016 /PRNewswire/ --
Sangamo BioSciences, Inc. (
NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that
Edward Lanphier, Sangamo's president and chief executive officer, will participate in the following upcoming conferences.
- Piper Jaffray GenomeRx Symposium, New York, NY, May 17-18, 2016Mr. Lanphier will participate in two panel discussion entitled "Approaches to Gene Integration: Lenti, AAV & More" and "The Cutting/Editing Edge" on May 17, 2016.
- 11th Annual World Stem Cells & Regenerative Medicine Congress, London, UK, May 18-20, 2016Mr. Lanphier will lead a roundtable discussion focused on infectious diseases on May 19, 2016.
About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures
® for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company's proprietary In Vivo Protein Replacement Platform™ (IVPRP) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its proprietary IVPRP approach, Sangamo is initiating Phase 1/2 clinical trials for hemophilia B, the first
in vivo genome editing application cleared by the
FDA, and MPS I. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics
® for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with
Shire International GmbH to develop therapeutics for
Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including
Dow AgroSciences and
Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at
www.sangamo.com.
No comments:
Post a Comment